Antibiotics Market Size, Share & Growth Trend Analysis Report By Type of Drug Class, Target Disease Indication, Type of Therapy, Route of Administration (2026 - 2035)

Figure 1.1 Executive Summary: Overall Market Landscape of Approved Antibiotic Generics

Figure 1.2 Executive Summary: Overall Market Landscape of Approved Antibiotic Brands

Figure 1.3 Executive Summary: Overall Market Landscape of Clinical -Stage Antibiotics

Figure 1.4 Executive Summary: Partnerships and Collaborations

Figure 1.5 Executive Summary: Clinical Trial Analysis

Figure 1.6 Executive Summary: Key Opinion Leaders

Figure 1.7 Executive Summary: Market Forecast and Opportunity Analysis

Figure 2.1 Classification of Antibiotics

Figure 2.2 History of Antibiotics

Figure 2.3 Mechanism of Action of Antibiotics

Figure 3.1 Approved Antibiotic Generics: Distribution by Year of Approval

Figure 3.2 Approved Antibiotic Generics: Distribution by Region(s) of Approval

Figure 3.3 Approved Antibiotic Generics: Distribution by Year and Region(s) of Approval

Figure 3.4 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Chemical Structure)

Figure 3.5 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Drug Class)

Figure 3.6 Approved Antibiotic Generics: Distribution by Mechanism of Action

Figure 3.7 Approved Antibiotic Generics: Distribution by Spectrum of Activity

Figure 3.8 Approved Antibiotic Generics: Distribution by Type of Target Bacteria(s)

Figure 3.9 Approved Antibiotic Generics: Distribution by Target Bacterial Strain(s)

Figure 3.10 Approved Antibiotic Generics: Distribution by Target Disease Indication(s)

Figure 3.11 Approved Antibiotic Generics: Distribution by Nature of Source

Figure 3.12 Approved Antibiotic Generics: Distribution by Type of Therapy

Figure 3.13 Approved Antibiotic Generics: Distribution by Route(s) of Administration

Figure 3.14 Approved Antibiotic Generics: Distribution by Dosage Form(s)

Figure 3.15 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Age)

Figure 3.16 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Gender)

Figure 3.17 Approved Antibiotic Generic Developers: Distribution by Year of Establishment

Figure 3.18 Approved Antibiotic Generic Developers: Distribution by Company Size

Figure 3.19 Approved Antibiotic Generic Developers: Distribution by Location of Headquarters

Figure 3.20 Most Active Players: Distribution by Number of Approved Generics

Figure 4.1 Approved Antibiotic Brands: Distribution by Year of Approval

Figure 4.2 Approved Antibiotic Brands: Distribution by Region(s) of Approval

Figure 4.3 Approved Antibiotic Brands: Distribution by Year and Region(s) of Approval

Figure 4.4 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Chemical Structure)

Figure 4.5 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Drug Class)

Figure 4.6 Approved Antibiotic Brands: Distribution by Mechanism of Action

Figure 4.7 Approved Antibiotic Brands: Distribution by Spectrum of Activity

Figure 4.8 Approved Antibiotic Brands: Distribution by Type of Target Bacteria(s)

Figure 4.9 Approved Antibiotic Brands: Distribution by Target Bacterial Strain(s)

Figure 4.10 Approved Antibiotic Brands: Distribution by Target Disease Indication(s)

Figure 4.11 Approved Antibiotic Brands: Distribution by Nature of Source

Figure 4.12 Approved Antibiotic Brands: Distribution by Type of Therapy

Figure 4.13 Approved Antibiotic Brands: Distribution by Route(s) of Administration

Figure 4.14 Approved Antibiotic Brands: Distribution by Dosage Form(s)

Figure 4.15 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Age)

Figure 4.16 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Gender)

Figure 4.17 Approved Antibiotic Brands: Distribution by Type of Innovation

Figure 4.18 Approved Antibiotic Brand Developers: Distribution by Year of Establishment

Figure 4.19 Approved Antibiotic Brand Developers: Distribution by Company Size

Figure 4.20 Approved Antibiotic Brand Developers: Distribution by Location of Headquarters

Figure 4.21 Most Active Players: Distribution by Number of Approved Brands

Figure 5.1 Clinical -Stage Antibiotics: Distribution by Status of Development

Figure 5.2 Clinical -Stage Antibiotics: Distribution by Stage of Development

Figure 5.3 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Chemical Structure)

Figure 5.4 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Drug Class)

Figure 5.5 Clinical -Stage Antibiotics: Distribution by Mechanism of Action

Figure 5.6 Clinical -Stage Antibiotics: Distribution by Spectrum of Activity

Figure 5.7 Clinical -Stage Antibiotics: Distribution by Type of Target Bacteria(s)

Figure 5.8 Clinical -Stage Antibiotics: Distribution by Target Bacterial Strain(s)

Figure 5.9 Clinical-Stage Antibiotics: Distribution by Target Disease Indication(s)

Figure 5.10 Clinical -Stage Antibiotics: Distribution by Therapeutic Area(s)

Figure 5.11 Clinical -Stage Antibiotics: Distribution by Nature of Source

Figure 5.12 Clinical -Stage Antibiotics: Distribution by Type of Therapy

Figure 5.13 Clinical -Stage Antibiotics: Distribution by Route(s) of Administration

Figure 5.14 Clinical -Stage Antibiotics: Distribution by Dosage Form(s)

Figure 5.15 Clinical -Stage Antibiotics: Distribution by Dosage Strength

Figure 5.16 Clinical -Stage Antibiotics: Distribution by Dosage Frequency

Figure 5.17 Clinical -Stage Antibiotics: Distribution by Dosing Period

Figure 5.18 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Age)

Figure 5.19 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Gender)

Figure 5.20 Clinical -Stage Antibiotics: Distribution by Special Designation Received

Figure 5.21 Clinical -Stage Antibiotic Developers: Distribution by Year of Establishment

Figure 5.22 Clinical -Stage Antibiotic Developers: Distribution by Company Size

Figure 5.23 Clinical -Stage Antibiotic Developers: Distribution by Location of Headquarters

Figure 5.24 Most Active Players: Analysis by Number of Clinical-stage Antibiotics

Figure 5.25 Most Active Players: Analysis by Number of Preclinical-stage Antibiotics

Figure 6.1 Bristol-Myers Squibb: Annual Revenues, 2017-2022 (USD Billion)

Figure 6.2 Bristol-Myers Squibb: Key Strategies

Figure 6.3 Bristol-Myers Squibb: Key Focus Areas

Figure 6.4 Daiichi Sankyo: Annual Revenues, 2017-9M 2022 (JPY Billion)

Figure 6.5 Daiichi Sankyo: Key Strategies

Figure 6.6 Daiichi Sankyo: Key Focus Areas

Figure 6.7 GlaxoSmithKline: Annual Revenues, 2017-2022 (USD Billion)

Figure 6.8 GlaxoSmithKline: Key Strategies

Figure 6.9 GlaxoSmithKline: Key Focus Areas

Figure 6.10 Melinta Therapeutics: Annual Revenues, 2017-6M 2019 (USD Billion)

Figure 6.11 Melinta Therapeutics: Key Strategies

Figure 6.12 Melinta Therapeutics: Key Focus Areas

Figure 6.13 Merck: Annual Revenues, 2017-2022 (USD Billion)

Figure 6.14 Merck: Key Strategies

Figure 6.15 Merck: Key Focus Areas

Figure 6.16 Pfizer: Annual Revenues, 2017-9M 2022 (USD Billion)

Figure 6.17 Pfizer: Key Strategies

Figure 6.18 Pfizer: Key Focus Areas

Figure 6.19 Company Profiles: Concluding Remarks

Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership

Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership

Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Figure 7.4 Partnerships and Collaborations: Distribution by Type of Partner

Figure 7.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner

Figure 7.6 Partnerships and Collaborations: Distribution by Company Size

Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size

Figure 7.8 Partnerships and Collaborations: Local and International Agreements

Figure 7.9 Partnerships and Collaborations: Distribution by Geography

Figure 7.10 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements

Figure 7.11 Most Active Players: Distribution by Number of Partnerships

Figure 7.12 Partnerships and Collaborations: Concluding Remarks

Figure 8.1 Clinical Trial Analysis: Distribution by Trial Registration Year

Figure 8.2 Clinical Trial Analysis: Distribution by Trial Status

Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase

Figure 8.4 Clinical Trial Analysis: Distribution by Type of Patient Population (based on Gender)

Figure 8.5 Clinical Trial Analysis: Key Focus Areas

Figure 8.6 Clinical Trial Analysis: Distribution by Type of Sponsor

Figure 8.7 Clinical Trial Analysis: Distribution by Geography

Figure 8.8 Clinical Trial Analysis: Distribution by Trial Status and Geography

Figure 8.9 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography

Figure 8.10 Clinical Trial Analysis: Distribution of Patient Population by Trial Status and Geography

Figure 8.11 Most Active Industry Players: Analysis by Number of Trials

Figure 8.12 Most Active Non-Industry Players: Analysis by Number of Trials

Figure 9.1 KOL Analysis: Distribution by Type of KOL

Figure 9.2 KOL Analysis: Distribution by Qualification

Figure 9.3 KOL Analysis: Distribution by Type of Organization

Figure 9.4 KOL Analysis: Distribution by Affiliated Organization

Figure 9.5 KOL Analysis: Distribution by Geographical Location of KOLs

Figure 9.6 KOL Analysis: Distribution by Target Disease Indication(s)

Figure 9.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)

Figure 9.8 Most Prominent KOLs: Peer Group 1 (Other Types of Investigators)

Figure 9.9 Most Prominent KOLs: Distribution by RA score

Figure 9.10 Most Prominent KOLs: Comparison of RA Score and Third-Party Score

Figure 9.11 KOL Analysis: Concluding Remarks

Figure 10.1 Drug-Pricing Analysis: Distribution by Geography

Figure 10.2 Key Antibiotic Developers: Outsourcing Trends

Figure 11.1 Dovprela (TB Alliance): Success Protocol Analysis

Figure 11.2 Fetroja (Shionogi): Success Protocol Analysis

Figure 11.3 Kimyrsa (Melinta Therapeutics): Success Protocol Analysis

Figure 11.4 Recarbrio (Merck): Success Protocol Analysis

Figure 11.5 Quofenix (Menarini): Success Protocol Analysis

Figure 11.6 Xenleta (Nabriva Therapeutics): Success Protocol Analysis

Figure 11.7 Success Protocol Analysis: Concluding Remarks

Figure 12.1 Global Antibiotics Market, 2023-2035 (USD Billion)

Figure 12.2 Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2035 (USD Billion)

Figure 12.3 Antibiotics Market for Aminoglycosides, 2023-2035 (USD Billion)

Figure 12.4 Antibiotics Market for Cephalosporins, 2023-2035 (USD Billion)

Figure 12.5 Antibiotics Market for Fluoroquinolones, 2023-2035 (USD Billion)

Figure 12.6 Antibiotics Market for Macrolides, 2023-2035 (USD Billion)

Figure 12.7 Antibiotics Market for Oxazolidinones, 2023-2035 (USD Billion)

Figure 12.8 Antibiotics Market for Penicillins, 2023-2035 (USD Billion)

Figure 12.9 Antibiotics Market for Sulphonamides, 2023-2035 (USD Billion)

Figure 12.10 Antibiotics Market for Tetracyclines, 2023-2035 (USD Billion)

Figure 12.11 Antibiotics Market for Other Classes, 2023-2035 (USD Billion)

Figure 12.12 Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Billion)

Figure 12.13 Antibiotics Market for Bacterial Infections, 2023-2035 (USD Billion)

Figure 12.14 Antibiotics Market for Dermatological/ Skin Infections, 2023-2035 (USD Billion)

Figure 12.15 Antibiotics Market for Gastrointestinal Infections, 2023-2035 (USD Billion)

Figure 12.16 Antibiotics Market for Nephrological Infections, 2023-2035 (USD Billion)

Figure 12.17 Antibiotics Market for Pulmonary Infections, 2023-2035 (USD Billion)

Figure 12.18 Antibiotics Market for Reproductive Tract Infections, 2023-2035 (USD Billion)

Figure 12.19 Antibiotics Market for Respiratory Tract Infections, 2023-2035 (USD Billion)

Figure 12.20 Antibiotics Market for Sexually Transmitted Diseases, 2023-2035 (USD Billion)

Figure 12.21 Antibiotics Market for Urinary Tract Infections, 2023-2035 (USD Billion)

Figure 12.22 Antibiotics Market for Other Bacterial Infections, 2023-2035 (USD Billion)

Figure 12.23 Antibiotics Market: Distribution by Type of Therapy, 2023 and 2035 (USD Billion)

Figure 12.24 Antibiotics Market for Monotherapies, 2023-2035 (USD Billion)

Figure 12.25 Antibiotics Market for Combination Therapies, 2023-2035 (USD Billion)

Figure 12.26 Antibiotics Market: Distribution by Route of Administration, 2023 and 2035 (USD Billion)

Figure 12.27 Antibiotics Market for Intravenous Therapies, 2023-2035 (USD Billion)

Figure 12.28 Antibiotics Market for Oral Therapies, 2023-2035 (USD Billion)

Figure 12.29 Antibiotics Market: Distribution by Geography, 2023 and 2035 (USD Billion)

Figure 12.30 Antibiotics Market in North America, 2023-2035 (USD Billion)

Figure 12.31 Antibiotics Market in Europe, 2023-2035 (USD Billion)

Figure 12.32 Antibiotics Market in Asia-Pacific, 2023-2035 (USD Billion)

Figure.13.33 Antibiotics Market in Rest of the World, 2023-2035 (USD Billion)

Figure.13.34 Aemcolo®: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.1 Arikayce®: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.2 Baxdela™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.3 Dalacin C: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.4 Dovprela®: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.5 Emrok: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.6 Emrok-O: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.7 Fetroja®: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.8 Kimyrsa™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.9 Lasvic®: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.10 Nuzyra®: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.11 Orbactiv™/Tenkasi: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.12 Ozanex™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.13 Quofenix: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.14 Recarbrio™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.15 Seysara™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.16 Solosec®: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.17 Vabomere™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.18 Xenleta™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.19 XEPI™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.20 Xerava™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.21 Xydalba®: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.22 Youxitai: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.23 Zemdri™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.24 Zerbaxa®: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.25 Zyvoxam®: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.26 Cefepime-Taniborbactam: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.27 CONTEPO™: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.28 Gepotidacin (GSK2140944): Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.29 MBK-01: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.30 MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.31 Nafithromycin (WCK 4873): Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.32 RHB-104 (rifabutin, rifabutin, and clofazimin): Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.33 RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.34 Ridinilazole (SMT 19969): Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.35 Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.36 Tebipenem HBr: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.37 WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.38 WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.39 XNW4107 (Funobactam): Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.40 Zabofloxacin: Sales Forecast, 2023-2035 (USD Billion)

Figure. 13.41 Zoliflodacin (ETX0914): Sales Forecast, 2023-2035 (USD Billion)

Table 3.1 Approved Antibiotic Generics: Information on Year of Approval, Region(s) of Approval, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action, and Spectrum of Activity

Table 3.2 Approved Antibiotic Generics: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Nature of Source and Type of Therapy

Table 3.3 Approved Antibiotic Generics: Information on Route(s) of Administration. Dosage Form(s), and Type of Patient Population (based on Age and Gender)

Table 3.4 Approved Antibiotic Generics: List of Developers

Table 4.1 Approved Antibiotic Brands: Information on Year of Approval, Region(s) of Approval, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action and Spectrum of Activity

Table 4.2 Approved Antibiotic Brands: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Nature of Source and Type of Therapy

Table 4.3 Approved Antibiotic Brands: Information on Route(s) of Administration, Dosage Form(s), Type of Patient Population (based on Age and Gender) and Type of Innovation

Table 4.4 Approved Antibiotic Brands: List of Developers

Table 5.1 Clinical -Stage Antibiotics: Information on Status of Development, Stage of Development, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action and Spectrum of Activity

Table 5.2 Clinical -Stage Antibiotics: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Therapeutic Area, Nature of Source and Type of Therapy

Table 5.3 Clinical -Stage Antibiotics: Information on Route(s) of Administration,Dosage Form(s), Dosage Strength, Dosage Frequency and Dosing Period

Table 5.4 Clinical -Stage Antibiotics: Information on Type of Patient Population (based on Age and Gender)

Table 5.5 Clinical -Stage Antibiotics: List of Developers

Table 6.1 Bristol-Myers Squibb: Product Portfolio

Table 6.2 Bristol-Myers Squibb: Recent Developments and Future Outlook

Table 6.3 Daiichi Sankyo: Product Portfolio

Table 6.4 Daiichi Sankyo: Recent Developments and Future Outlook

Table 6.5 GlaxoSmithKline: Product Portfolio

Table 6.6 GlaxoSmithKline: Recent Developments and Future Outlook

Table 6.7 Melinta Therapeutics: Product Portfolio

Table 6.8 Melinta Therapeutics: Recent Developments and Future Outlook

Table 6.9 Merck: Product Portfolio

Table 6.10 Merck: Recent Developments and Future Outlook

Table 6.11 Pfizer: Product Portfolio

Table 6.12 Pfizer: Recent Developments and Future Outlook

Table 7.1 Antibiotics: List of Partnerships and Collaborations

Table 8.1 Antibiotics: List of Clinical Trials

Table 9.1 Antibiotics: List of Key Opinion Leaders (KOLs)

Table 10.1 Antibiotics Industry: List of Recent Expansions

Table 11.1 Sales Forecast: List of Approved Antibiotics

Table 12.1 Sales Forecast: List of Clinical-stage Antibiotics

Table 13.1 Approved Antibiotic Generics: Distribution by Year of Approval

Table 13.2 Approved Antibiotic Generics: Distribution by Region(s) of Approval

Table 13.3 Approved Antibiotic Generics: Distribution by Year and Region(s) of Approval

Table 13.4 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Chemical Structure)

Table 13.5 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Drug Class)

Table 13.6 Approved Antibiotic Generics: Distribution by Mechanism of Action

Table 13.7 Approved Antibiotic Generics: Distribution by Spectrum of Activity

Table 13.8 Approved Antibiotic Generics: Distribution by Type of Target Bacteria(s)

Table 13.9 Approved Antibiotic Generics: Distribution by Target Bacterial Strain(s)

Table 13.10 Approved Antibiotic Generics: Distribution by Target Disease Indication(s)

Table 13.11 Approved Antibiotic Generics: Distribution by Nature of Source

Table 13.12 Approved Antibiotic Generics: Distribution by Type of Therapy

Table 13.13 Approved Antibiotic Generics: Distribution by Route(s) of Administration

Table 13.14 Approved Antibiotic Generics: Distribution by Dosage Form(s)

Table 13.15 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Age)

Table 13.16 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Gender)

Table 13.17 Approved Antibiotic Generic Developers: Distribution by Year of Establishment

Table 13.18 Approved Antibiotic Generic Developers: Distribution by Company Size

Table 13.19 Approved Antibiotic Generic Developers: Distribution by Location of Headquarters

Table 13.20 Most Active Players: Distribution by Number of Approved Generics

Table 13.21 Approved Antibiotic Brands: Distribution by Year of Approval

Table 13.22 Approved Antibiotic Brands: Distribution by Region(s) of Approval

Table 13.23 Approved Antibiotic Brands: Distribution by Year and Region(s) of Approval

Table 13.24 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Chemical Structure)

Table 13.25 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Drug Class)

Table 13.26 Approved Antibiotic Brands: Distribution by Mechanism of Action

Table 13.27 Approved Antibiotic Brands: Distribution by Spectrum of Activity

Table 13.28 Approved Antibiotic Brands: Distribution by Type of Target Bacteria(s)

Table 13.29 Approved Antibiotic Brands: Distribution by Target Bacterial Strain(s)

Table 13.30 Approved Antibiotic Brands: Distribution by Target Disease Indication(s)

Table 13.31 Approved Antibiotic Brands: Distribution by Nature of Source

Table 13.32 Approved Antibiotic Brands: Distribution by Type of Therapy

Table 13.33 Approved Antibiotic Brands: Distribution by Route(s) of Administration

Table 13.34 Approved Antibiotic Brands: Distribution by Dosage Form(s)

Table 13.35 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Age)

Table 13.36 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Gender)

Table 13.37 Approved Antibiotic Brands: Distribution by Type of Innovation

Table 13.38 Approved Antibiotic Brand Developers: Distribution by Year of Establishment

Table 13.39 Approved Antibiotic Brand Developers: Distribution by Company Size

Table 13.40 Approved Antibiotic Brand Developers: Distribution by Location of Headquarters

Table 13.41 Most Active Players: Distribution by Number of Approved Brands

Table 13.42 Clinical -Stage Antibiotics: Distribution by Status of Development

Table 13.43 Clinical -Stage Antibiotics: Distribution by Stage of Development

Table 13.44 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Chemical Structure)

Table 13.45 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Drug Class)

Table 13.46 Clinical -Stage Antibiotics: Distribution by Mechanism of Action

Table 13.47 Clinical -Stage Antibiotics: Distribution by Spectrum of Activity

Table 13.48 Clinical -Stage Antibiotics: Distribution by Type of Target Bacteria(s)

Table 13.49 Clinical -Stage Antibiotics: Distribution by Target Bacterial Strain(s)

Table 13.50 Clinical -Stage Antibiotics: Distribution by Target Disease Indication(s)

Table 13.51 Clinical -Stage Antibiotics: Distribution by Therapeutic Area(s)

Table 13.52 Clinical -Stage Antibiotics: Distribution by Nature of Source

Table 13.53 Clinical -Stage Antibiotics: Distribution by Type of Therapy

Table 13.54 Clinical -Stage Antibiotics: Distribution by Route(s) of Administration

Table 13.55 Clinical -Stage Antibiotics: Distribution by Dosage Form(s)

Table 13.56 Clinical -Stage Antibiotics: Distribution by Dosage Strength

Table 13.57 Clinical -Stage Antibiotics: Distribution by Dosage Frequency

Table 13.58 Clinical -Stage Antibiotics: Distribution by Dosing Period

Table 13.59 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Age)

Table 13.60 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Gender)

Table 13.61 Clinical -Stage Antibiotics: Distribution by Special Designation Received

Table 13.62 Clinical -Stage Antibiotic Developers: Distribution by Year of Establishment

Table 13.63 Clinical -Stage Antibiotic Developers: Distribution by Company Size

Table 13.64 Clinical -Stage Antibiotic Developers: Distribution by Location of Headquarters

Table 13.65 Most Active Players: Analysis by Number of Clinical-stage Antibiotics

Table 13.66 Most Active Players: Analysis by Number of Preclinical-stage Antibiotics

Table 13.67 Partnerships and Collaborations: Distribution by Year of Partnership

Table 13.68 Partnerships and Collaborations: Distribution by Type of Partnership

Table 13.69 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Table 13.70 Partnerships and Collaborations: Distribution by Type of Partner

Table 13.71 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner

Table 13.72 Partnerships and Collaborations: Distribution by Company Size

Table 13.73 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size

Table 13.74 Partnerships and Collaborations: Local and International Agreements

Table 13.75 Partnerships and Collaborations: Distribution by Geography

Table 13.76 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements

Table 13.77 Most Active Players: Distribution by Number of Partnerships

Table 13.78 Clinical Trial Analysis: Distribution by Trial Registration Year

Table 13.79 Clinical Trial Analysis: Distribution by Trial Status

Table 13.80 Clinical Trial Analysis: Distribution by Trial Phase

Table 13.81 Clinical Trial Analysis: Distribution by Type of Patient Population (based on Gender)

Table 13.82 Clinical Trial Analysis: Distribution by Type of Sponsor

Table 13.83 Clinical Trial Analysis: Distribution by Geography

Table 13.84 Clinical Trial Analysis: Distribution by Trial Status and Geography

Table 13.85 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography

Table 13.86 Clinical Trial Analysis: Distribution of Patient Population by Trial Status and Geography

Table 13.87 Most Active Industry Players: Analysis by Number of Trials

Table 13.88 Most Active Non-Industry Players: Analysis by Number of Trials

Table 13.89 KOL Analysis: Distribution by Type of KOL

Table 13.90 KOL Analysis: Distribution by Qualification

Table 13.91 KOL Analysis: Distribution by Type of Organization

Table 13.92 KOL Analysis: Distribution by Affiliated Organization

Table 13.93 KOL Analysis: Distribution by Geographical Location of KOLs

Table 13.94 KOL Analysis: Distribution by Target Disease Indication(s)

Table 13.95 Global Antibiotics Market: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.96 Antibiotics Market: Distribution by Type of Antibiotic (based on Drug Class), 2023 and 2035 (USD Billion)

Table 13.97 Antibiotics Market for Aminoglycosides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.98 Antibiotics Market for Cephalosporins, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.99 Antibiotics Market for Fluoroquinolones, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.100 Antibiotics Market for Macrolides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.101 Antibiotics Market for Oxazolidinones, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.102 Antibiotics Market for Penicillins, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.103 Antibiotics Market for Sulphonamides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.104 Antibiotics Market for Tetracyclines, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.105 Antibiotics Market for Other Classes, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.106 Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Billion)

Table 13.107 Antibiotics Market for Bacterial Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.108 Antibiotics Market for Dermatological/ Skin Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.109 Antibiotics Market for Gastrointestinal Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.110 Antibiotics Market for Nephrological Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.111 Antibiotics Market for Pulmonary Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.112 Antibiotics Market for Reproductive Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.113 Antibiotics Market for Respiratory Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.114 Antibiotics Market for Sexually Transmitted Diseases, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.115 Antibiotics Market for Urinary Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.116 Antibiotics Market for Other Bacterial Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.117 Antibiotics Market: Distribution by Type of Therapy, 2023 and 2035 (USD Billion)

Table 13.118 Antibiotics Market for Monotherapies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.119 Antibiotics Market for Combination Therapies, 2023-2035 (USD Billion)

Table 13.120 Antibiotics Market: Distribution by Route of Administration, 2023 and 2035 (USD Billion)

Table 13.121 Antibiotics Market for Intravenous Therapies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.122 Antibiotics Market for Oral Therapies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.123 Antibiotics Market: Distribution by Geography, 2023 and 2035

Table 13.124 Antibiotics Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.125 Antibiotics Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.126 Antibiotics Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.127 Antibiotics Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.128 Aemcolo®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.129 Arikayce®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.130 Baxdela™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion))

Table 13.131 Dalacin C: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.132 Dovprela®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.133 Emrok: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.134 Emrok-O: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.135 Fetroja®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.136 Kimyrsa™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.137 Lasvic®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.138 Nuzyra®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.139 Orbactiv™/Tenkasi: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.140 Ozanex™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.141 Quofenix: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.142 Recarbrio™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.143 Seysara™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.144 Solosec®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.145 Vabomere™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.146 Xenleta™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.147 XEPI™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.148 Xerava™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.149 Xydalba®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.150 Youxitai: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.151 Zemdri™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.152 Zerbaxa®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.153 Zyvoxam®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.154 Cefepime-Taniborbactam: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.155 CONTEPO™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.156 Gepotidacin (GSK2140944): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.157 MBK-01: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.158 MRX-4 (Contezolid Acefosamil): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.159 Nafithromycin (WCK 4873): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.160 RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.161 RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.162 Ridinilazole (SMT 19969): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.163 Sulopenem- etzadroxil- probenecid: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.164 Tebipenem HBr: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.165 WCK 4282 (Cefepime-Tazobactam): Sales Forecast, , Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.166 WCK 5222 (cefepime + zidebactam): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.167 XNW4107 (Funobactam): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.168 Zabofloxacin: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 13.169 Zoliflodacin (ETX0914): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Please reach out to our team for more details.